Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Changchun GeneScience Pharma FGFR2/FGFR3 compound 23
- Development stage
- Preclinical
- Lead developer
- Changchun GeneScience Pharmaceutical
01
Overview
Changchun GeneScience Pharma FGFR2/FGFR3 compound 23: sourced facts only. name: "Through structural hybridization of Tyra-300 and LY2874455, we developed compound 23, a new dual-target FGFR2/3 inhibitor demonstrating potent activity against both wild-type and mutant FGFR3."; target: "Through structural hybridization of Tyra-300 and LY2874455, we developed compound 23, a new dual-target FGFR2/3 inhibitor demonstrating potent activity against both wild-type and mutant FGFR3."; target: "Through structural hybridization of Tyra-300 and LY2874455, we developed compound 23, a new dual-target FGFR2/3 inhibitor demonstrating potent activity against both wild-type and mutant FGFR3."; developer: "Changchun GeneScience Pharmaceuticals Co., Ltd., Changchun 130021, China."; stage: "In preclinical ACH mouse models, compound 23 showed a dose-dependent improvement in growth rate, with significantly enhanced efficacy versus infigratinib at equivalent doses."
02
Targets
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Go deeper on Changchun GeneScience Pharma FGFR2/FGFR3 compound 23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Changchun GeneScience Pharma FGFR2/FGFR3 compound 23.
Work on Changchun GeneScience Pharma FGFR2/FGFR3 compound 23? Claim this page to correct or add information. Claim this page